What Eagle Pharmaceuticals does

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is a publicly traded specialty pharmaceutical company founded in 2007 and headquartered at 50 Tice Blvd, Suite 315, Woodcliff Lake, New Jersey, with additional offices in Cambridge, Massachusetts; Indianapolis, Indiana; and Jupiter, Florida. The company develops, acquires, and commercializes injectable pharmaceutical products primarily in critical care, oncology, and rare/orphan disease indications, employing between 101 and 250 people. Its marketed portfolio includes BYFAVO (remimazolam) for procedural sedation, PEMFEXY (pemetrexed) for non-small cell lung cancer and malignant pleural mesothelioma, BELRAPZO and BENDEKA (bendamustine) for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma, RYANODEX (dantrolene sodium) for malignant hyperthermia, a non-alcohol formulation of Docetaxel, and Argatroban for anticoagulation. The pipeline includes CAL02 (a first-in-class anti-toxin for severe community-acquired bacterial pneumonia with FDA Fast-Track and QIDP designations, in global Phase 2 across approximately 120 centers in 22 countries), ENA-001 (an agnostic respiratory stimulant being developed by partner Enalare for multiple indications of respiratory depression), and EA-114 (a proprietary fulvestrant formulation for HR-positive metastatic breast cancer, with NDA filing planned for 2024).

Eagle's core technology approach is built on the FDA 505(b)(2) regulatory pathway: identifying approved injectable molecules whose clinical utility can be improved through second-generation reformulations — improving stability, reconstitution time, dosing convenience, or removing undesirable excipients — and advancing them through proprietary manufacturing processes. Patents include pending IP on stable pemetrexed formulations (IL324306A). Revenue is generated through unit sales of FDA-approved injectable products to hospitals, healthcare providers, and health systems; pricing is not publicly disclosed and is negotiated through standard pharmaceutical distribution channels. In the United States, Eagle has historically operated a fully integrated commercial team selling directly to hospitals and health systems, while ex-U.S. commercialization is executed through exclusive distribution partners — most prominently ACA Pharma, which distributes RYANODEX and previously Barhemsys across Hong Kong, Macau, Singapore, Greater China, Europe, Latin America, the Middle East, and Asia-Pacific. Charitable in-kind partnerships (Medical Missions for Children, Global Smile Foundation, World Pediatrics) supply RYANODEX for surgical missions but are not commercial revenue channels.

The company is navigating significant operational and financial stress. Following the June 2022 acquisition of Acacia Pharma Group plc for approximately €94.7 million, which added BARHEMSYS and BYFAVO with projected peak U.S. sales of $275 million against a $3.1 billion combined market, Eagle has since announced the divestiture of Barhemsys and agreed in March 2026 to pay $9.5 million to settle an investor class action alleging "channel stuffing" to inflate reported revenue. The Board has extended a limited duration stockholder rights plan through October 30, 2026, and the company has disclosed substantial doubt about its ability to continue as a going concern; share price was reported at approximately $0.35 with an apparent equity valuation of $4.55 million as of April 2026.

Name

Eagle Pharmaceuticals

Legal name

Eagle Pharmaceuticals, Inc.

Website

https://eagleus.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

Eagle Pharmaceuticals is a publicly traded specialty pharma company (NASDAQ: EGRX) that develops, acquires, and commercializes injectable drugs for critical care, oncology, and rare diseases, selling directly to U.S. hospitals and via regional distributors internationally.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Injectables)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Injectable pharmaceuticals
• Specialty pharmaceuticals
• Critical care drugs
• Oncology injectables
• 505(b)(2) drug development

Headquarters

HQ city

Woodcliff Lake

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Pharmaceutical Product Sales: Eagle Pharmaceuticals generates revenue through the sale of FDA-approved injectable pharmaceutical products including BYFAVO, PEMFEXY, BELRAPZO, RYANODEX, BENDEKA, Docetaxel Injection, and Argatroban. Revenue is derived from product sales to healthcare providers, hospitals, and health systems.
2. Peak Sales from Acquired Products: Following the 2022 acquisition of Acacia Pharma Group plc for approximately €94.7 million, Eagle projects peak sales of $275 million in the U.S. from BARHEMSYS and BYFAVO combined, targeting a $3.1 billion combined market.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Eagle Pharmaceuticals discovers, develops, manufactures, and commercializes injectable pharmaceutical products primarily for critical care and oncology indications. The company markets FDA-approved injectables including BYFAVO, PEMFEXY, BELRAPZO, BENDEKA, RYANODEX, BARHEMSYS, Docetaxel Injection, and Argatroban to hospitals and healthcare systems, primarily utilizing the 505(b)(2) regulatory pathway to deliver improved second-generation formulations of existing molecules.

Product overview

Eagle Pharmaceuticals is a specialty pharmaceutical company focused on developing, acquiring, and commercializing injectable treatments for critical care and oncology patients. The company's marketed product portfolio includes BYFAVO (procedural sedation), PEMFEXY (oncology/lung cancer), BELRAPZO and BENDEKA (bendamustine formulations for CLL and NHL), RYANODEX (malignant hyperthermia treatment), DOCETAXEL (non-alcohol formula), and ARGATROBAN (anticoagulation). The company operates through a fully integrated commercial team with flexibility to market products with or without a partner, primarily utilizing the 505(b)(2) regulatory pathway. Eagle's pipeline includes CAL021 for severe pneumonia, ENA-001 for respiratory depression, and EA-114 for breast cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• BYFAVO (remimazolam) for injection A benzodiazepine indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy. Marketed to hospitals, healthcare providers, and health systems.
• PEMFEXY (pemetrexed injection) A pemetrexed injection indicated in combination with cisplatin for initial treatment of non-squamous non-small cell lung cancer and malignant pleural mesothelioma, and as a single agent for maintenance treatment and recurrent disease. Sold to oncology providers and health systems.
• BELRAPZO (bendamustine hydrochloride injection) A bendamustine hydrochloride injection indicated for treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of rituximab treatment. Marketed to oncology providers and hospitals.
• RYANODEX (dantrolene sodium) for injectable suspension A dantrolene sodium injectable suspension indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for prevention of malignant hyperthermia in patients at high risk. Distributed to hospitals and used during surgical and emergency procedures.
• BENDEKA (bendamustine hydrochloride) Injection A bendamustine hydrochloride injection indicated for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of rituximab treatment. Sold to hospitals and oncology practices.
• DOCETAXEL Injection (non-alcohol formula) A docetaxel injection formulation without alcohol for oncology treatment, offering a differentiated non-alcohol formulation for patients and providers.
• ARGATROBAN (Argatroban Injection) An argatroban injection product for anticoagulation therapy, sold to hospitals and acute care settings.
• BARHEMSYS (amisulpride) injection An amisulpride injection indicated for the prevention and treatment of post-operative nausea and vomiting in adult patients, marketed to hospitals and perioperative care teams.

Quantifiable outcome

• RYANODEX vials were available for over 250 surgeries in 2018 in Guatemala, Peru, Belize, El Salvador, and Tanzania.
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• ACA PharmacoreChannel Partner/ Reseller/ Distributor · 24 November 2025ACA Pharma expanded its ex-U.S. territory for distribution of RYANODEX, developed by Eagle Pharmaceuticals for malignant hyperthermia, across Europe, Latin America, the Middle East, and Asia-Pacific, with efforts focused on registration, clinician education, and supply chain stability.
• Indian Society of AnaesthesiologistsminorStrategic or Co-development Partner · 20 November 2025The Indian Society of Anaesthesiologists hosted a virtual nationwide launch of Ryanodex in India to improve emergency response to malignant hyperthermia. Eagle Pharmaceuticals and ACA Pharma are involved as manufacturer and distribution partners, respectively.
• ACA PharmacoreChannel Partner/ Reseller/ Distributor · 9 October 2025ACA Pharma signed an exclusive distribution agreement with Eagle Pharmaceuticals to commercialize Ryanodex and Barhemsys across Hong Kong, Macau, Singapore, and Greater China. The products have completed or are progressing in regulatory approval processes in these regions, with plans for expansion into Latin America, Europe, and other areas.
• Medical Missions for ChildrenminorStrategic or Co-development PartnerEagle Pharmaceuticals partners with Medical Missions for Children to provide RYANODEX during cleft lip and palate surgeries and other reconstructive procedures for children globally.
• Global Smile FoundationminorStrategic or Co-development PartnerEagle provides RYANODEX for surgical teams performing cleft palate and other reconstructive surgeries globally through partnership with Global Smile Foundation.
• World PediatricsminorStrategic or Co-development PartnerEagle partners with World Pediatrics to provide surgical care and RYANODEX availability during medical missions in Guatemala, Peru, Belize, El Salvador, and Tanzania.
• EnalarecoreStrategic or Co-development PartnerIn August 2022, Eagle acquired a 17% equity stake in Enalare with an option to purchase remaining shares upon achievement of specified milestones. Enalare is developing ENA-001, an investigational new chemical entity as an agnostic respiratory stimulant for multiple patient populations experiencing respiratory depression.
• Codagenix, Inc.minorOthersDr. Luciana Borio, Eagle board member, serves on the Scientific Advisory Board of Codagenix, Inc. This is a board-level advisory relationship rather than a commercial partnership.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Hikma Pharmaceuticals: Specialty injectable pharmaceutical manufacturer with broad hospital portfolio including oncology and critical-care sterile injectables, very closely comparable to Eagle's injectable specialty focus. Both focus on niche, hospital-administered injectable products with U.S. and international distribution.
• Amphastar Pharmaceuticals: Specialty injectable pharmaceutical company focused on hospital and ambulatory-care injectable products including oncology, critical care, and complex formulations. Comparable in size, product mix, and U.S.-centric hospital channel focus to Eagle Pharmaceuticals.
• ANI Pharmaceuticals: Specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals, including injectables used in hospital settings. Comparable mid-cap specialty pharma with similar 505(b)(2)/reformulation orientation.
• Lannett Company: U.S. specialty and generic pharmaceutical manufacturer with injectables and solid oral dose capabilities. Comparable small/mid-cap specialty pharma operating in similar hospital channels with parallel reformulation focus.

Broad incumbents

• Fresenius Kabi: Large-volume global manufacturer of injectable pharmaceuticals, IV drugs, and clinical nutrition products widely used in hospitals and critical care. Direct overlap with Eagle in injectable hospital products but at much broader scale and across many more geographies.
• Hospira (Pfizer): Pfizer's hospital injectable franchise built on the Hospira acquisition, a dominant supplier of sterile injectables including oncology and sedation products. Provides the established branded competitor that Eagle's injectables compete against in hospital formularies.
• Teva Pharmaceutical Industries: Global pharmaceutical manufacturer with a sizable specialty/generic injectable portfolio including oncology and critical-care sterile products. Comparable to Eagle across several of its hospital injectable SKUs, though Teva operates at vastly greater scale and breadth.
• Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company with a focus on branded specialty products in hospital and critical care settings. Comparable in therapeutic areas (hospital injectables, oncology) and in channel reach to hospitals.
• Endo International / Par Pharmaceutical: Specialty and generic pharmaceutical company with a notable sterile injectable franchise and history of branded specialty product development. Comparable on injectable hospital strategy and parallel 505(b)(2)-style reformulation work.

Others

• Acacia Pharma (now part of Eagle): Acquired by Eagle Pharmaceuticals in 2022 for ~€94.7M. Acacia's BARHEMSYS and BYFAVO are now core Eagle products, making the legacy Acacia entity the closest intra-portfolio benchmark for hospital/acute-care injectable economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/eaglepharm
• Facebookfacebook.com/eaglepharmaceuticals
• LinkedInlinkedin.com/company/eagle-pharmaceuticals-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eagle Pharmaceuticals